Assessing the Growing Role & the Demand of Apps in Managing the Chronic Diseases

Neurology

Biogen’s ALS drug Tofersen (BIIB067); Pha...

Biogen’s tofersen fails to meet the primary goal in the Phase III ALS trial Biogen has announced that its investigational antisense drug, tofersen (BIIB067), flunked to meet the primary goal of Pha...

Oct 19, 2021

recent-biotech-pharma-news-for-brickell-bms-amydis-gensight-cybrexa
Brickell to Submit New Drug Application to FDA; Twin Health Raises $140M; BMS’ Deucravacitinib; Lando Biopharma’s LABP-104 gets Approval; NIH Grant of $ 3 M to Amydis; FDA Grant to GenSight’ GS030

Brickell Plans to Submit New Drug Application to FDA for gel Brickell Biotech will request the FDA in mid-2022 to approve its gel for excessive underarm sweating after decreasing sweat production and disease severity in two pivotal trials.  The gel achieved statistical significance in lessening the sever...

Find More
Digital-Therapeutics-for-depression
Evaluating the Role of Digital Therapeutics as an Alternative to Conventional Therapies for Depression

Depression is a mental condition characterized by prolonged series of poor moods, loss of interest and enjoyment in ordinary activities, and low energy, all of which contribute to varying degrees of social and vocational dysfunction. Depression is a chronic condition that affects a person's ability to work, quality...

Find More
medtech-news-updates-for-iotamotion-recor-natera-boston-scientific
Amber Implants VCFix spinal system; iotaMotion’s iotaSOFT Insertion System; Boston Scientific acquires Baylis; ReCor’s Paradise Ultrasound Renal Denervation; Boston Scientific’s Ranger Drug-Coated Balloon; Natera’s Prospera

Amber Implants VCFix® spinal system obtains US FDA Breakthrough designation  On October 05, 2021, the US Food and Drug Administration (FDA) granted the Breakthrough Device Designation to VCFix® spinal system, a next-generation spinal implant for spinal injuries developed by Amber Implants, a Netherlands-bas...

Find More

More Views & Analysis

myasthenia-gravis-treatment-market-growth-size-therapies-forecast-and-key-companies
Exploring the Market Potential of the Upcoming Therapies for the Myasthenia Gravis

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It occurs when the communication between nerve cells and muscles is disrupted. This impairment prevents critical muscle contractions from occurring, resulting in muscle weakness. This disease is associated with antibodies directed a...

Find More

medtech-happenings-for-neurolief-paige-bionaut-retina-medtronic
RETINA-AI Health declares positive results; Medtronic’s Hugo robotic-assisted surgery system; Boston Scientific acquires Devoro Medical; Paige obtains first-ever FDA approval

RETINA-AI Health, Inc. declares positive pivotal study results for the RETINA-AI Galaxy™ autonomous Diabetic Retinopathy screening device On September 20, 2021, RETINA-AI Health, Inc. announced optimistic results from the pivotal study of the RETINA-AI Galaxy™, a multi-device compatible autonomous ...

Find More

pharma-biotech-news-updates-for-innovent-biohaven-delix-intracellular-therapies
UNION Therapeutics-Innovent’s collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular’s CAPLYTA Phase III study

Innovent, UNION Therapeutics Set to Advance Dermatology Market in China  Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China. Orismilast ...

Find More

west-syndrome-market-epidemiology-therapies-treatment-therapeutics-cagr-trends-size-share-growth
Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epileptic Encephalopathy that displays an umbrella of symptoms such as seizures known as epileptic (infantile) spasms, gross EEG abnormalities of hypsarrhythmia and intellectual disability.  There are many different causes of epi...

Find More

pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics
FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A f...

Find More

pharma-news-updates-for-roche-mayo-clinic-owlstone-transmedics-google
Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indic...

Find More

Schizophrenia is a severe mental illness that interferes with a person's ability to think clearly, m.....

Find More

It was assumed initially that Alzheimer’s Disease was a rare condition, but now it is considered t.....

Find More

Digital health technologies can fill the current gaps in oncology care while rebalancing the existin.....

Find More

A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 mi.....

Find More

Today, the sedentary lifestyle adopted among people has led to cause a myriad of underlying diseases.....

Find More

Acute myeloid leukemia (AML), also called acute myelogenous leukemia and acute nonlymphocytic leukem.....

Find More